The advantages of cell therapy in the treatment of major diseases are increasingly evident! Pudong Innovative Pharmaceutical Enterprises Continuously Make Efforts to Benefit More Patients

Tech 2023-10-20 12:42:26 Source: Network

In recent years, under the new background of building future industries in the country and Shanghai, Pudong has actively sought and laid out new tracks and directions. Currently, a number of innovative entities have been introduced and gathered in related fields such as targeted drugs, synthetic biology, AI+new drug research and development, new conjugated drugs, new protein degrading drugs, cell drugs, etc

In recent years, under the new background of building future industries in the country and Shanghai, Pudong has actively sought and laid out new tracks and directions. Currently, a number of innovative entities have been introduced and gathered in related fields such as targeted drugs, synthetic biology, AI+new drug research and development, new conjugated drugs, new protein degrading drugs, cell drugs, etc. Among them, the advantages of cell therapy, which is the first to "enter" the race track, in the treatment of major diseases have become increasingly apparent.

According to the latest data statistics, from January to August this year, Shanghai received a total of 133 clinical approvals for Class 1 innovative drugs, including 20 clinical trial approvals for cell and gene therapy. Pudong enterprises have demonstrated extraordinary strength.

Enabling cellular immunotherapy to benefit more patients

Cell and Gene Therapy (CGT) is an important "new track" in global technology and industry competition. On this emerging track, as of June 2023, Zhangjiang in Pudong accounts for 3/5 of the registered clinical trial projects for cell and gene therapy in Shanghai and 1/4 of the total in China, which have been approved nationwide. It has also taken the lead in launching China's first and second CAR-T cell drugs.

CAR-TEnabling cellular immunotherapy to benefit more patients

Aunt Qin achieved complete remission (CR) of the disease in the first month after infusion, which gave us great confidence in our treatment. Subsequent follow-up has been in a continuous state of remission. Currently, Aunt Qin has been following up at our lymphoma CAR-T clinic at Ruijin Hospital for more than five years. I am happy to tell her that you are already a healthy individual and can enjoy your old age to the fullest Yan Zixun, one of the attending doctors, introduced the situation of Aunt Qin's follow-up to the present day.

In the view of Professor Xu Pengpeng from the Hematology Department of Ruijin Hospital, the clinical development and marketing application of CAR-T in China has provided more clinical doctors with better anti-cancer weapons and also brought dawn of cure to patients.

CAR-T is an epoch-making treatment method. Previously, we were only limited to targeted therapy and chemotherapy, and more focused on the treatment of the tumor itself. CAR-T has changed this concept, "said Professor Xu Pengpeng." We are also exploring more possibilities, such as combination medication

The birth of CAR-T therapy marks another breakthrough step for humanity in overcoming tumors. The launch of Pudong CAR-T products has driven researchers to rush into the cell therapy track. As the concentration of innovation continues to increase, Pudong's unique GOI program, the Open Innovation Center for Large Enterprises, quickly infiltrates this field, including providing research and development assembly services for startups, including gene and cell therapy, AI drug screening, gene editing, and more.

The entire industry chain of Pudong CGT has taken shape in Zhangjiang

Since the beginning of this year, there have been good news in the Zhangjiang CGT industry, such as the official approval of the clinical trial application for the first and second global CAR-T cell therapy product targeting GPRC5D in China, and the first domestic universal NK cell therapy product targeting GPRC5D, which is about to officially enter the clinical phase I research phase.

In response to the challenges of strong technological innovation and large initial investment in gene therapy products, Shanghai has further improved its ecosystem of technological innovation and industrial development, promoting high-quality development of the biopharmaceutical industry.

As proposed in the newly released "Shanghai Action Plan for Promoting Gene Therapy Technology Innovation and Industrial Development (2023-2025)" (hereinafter referred to as the "Action Plan"), by 2025, Shanghai's gene therapy technology innovation strategy capability will be further enhanced, clinical research and transformation application capabilities will be further enhanced, the innovation system will be further improved, and the industrial ecology will be further optimized; Build more than 5 clinical medical research centers and demonstration research wards in gene therapy and related fields; Introduce and cultivate more than 15 leading and backbone enterprises in the gene therapy industry; 1-2 innovative products applied for listing.

This is a policy measure that systematically plans to promote gene therapy in the next three years, following the release of the Shanghai Action Plan for Promoting Cell Therapy Technology Innovation and Industrial Development (2022-2024) last year. The Action Plan includes 4 aspects, 12 major tasks, and 8 safeguard measures, aiming to enhance the innovative policy sources and clinical research transformation capabilities in the field of gene therapy, enhance the accessibility of gene therapy products, and enhance the level of industrial development.

It is worth noting that the Action Plan also points out to enhance the level of industrial development and strengthen the "1+1" industrial spatial layout. Among them, with Pudong Zhangjiang Cell and Gene Industry Park as the core, we will build an international gene industry landmark and create a cluster for gene therapy technology innovation and industrial development.

At present, Zhangjiang Cell and Gene Industry Park has gathered over 100 upstream and downstream related enterprises in the cell and gene industry chain. In November, the fourth Zhangjiang International Summit on Cell and Gene Therapy Industry is also about to be held. After three years, the summit has become one of the most influential event brands in the field of cell and gene therapy in China, gradually developing into a platform for cooperation and exchange across the entire industry chain of cell and gene therapy in China.

Pudong is planning to lay out an emerging track in the field of biopharmaceutical industry. In addition to the cell and gene therapy industries being key areas for layout and promotion, synthetic biology is also gradually growing in Pudong.

Text: Yang Zhenying

Editor: Zhu Yikai

Source of this article: Pudong released official WeChat

Column Editor in Chief: Qin Hong Text Editor: Yang Rong

Source: Author: Published by Pudong

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: of The advantages cell therapy in the treatment major